Efficacy and safety of 12-hour versus 24-hour magnesium sulfate in management of patients with pre-eclampsia and eclampsia: a systematic review and meta-analysis
Open Access
- 25 July 2024
- journal article
- research article
- Published by Springer Nature in BMC Women's Health
- Vol. 24 (1) , 1-11
Abstract
Introduction: Magnesium sulfate is the most utilized anticonvulsant for treating patients with eclampsia and pre-eclampsia. The purpose of this study is to determine whether the 12-h regimen of magnesium sulfate outweighs the 24-h regimen in both efficacy and safety in the management of patients with mild or severe pre-eclampsia and eclampsia. Methods: We searched six electronic databases: PubMed, Scopus, Web of Science, Cochrane Library, Ovid, and Google Scholar. This search was conducted to yield any studies that were published until 15 January 2023. We did the statistical analysis plan by Review Manager Software version 5.4. Results: We included 13 randomized control trials with 2813 patients in this systematic review. Our meta-analysis revealed that there were no statistically significant differences between the 12-h regimen of the magnesium sulfate group and the 24-h regimen of the magnesium sulfate group in our outcome of interest: occurrence of seizure (RD: -0.00, 95% CI [-0.01, 0.00], P = 0.56), diminished deep tendon reflexes (RD: -0.00, 95% CI [-0.01, 0.01], P = 0.80), respiratory depression (RD: -0.00, 95% CI [-0.02, 0.01], P = 0.57), and pulmonary edema (RD: -0.00, 95% CI [-0.01, 0.01], P = 0.85). Conclusion: Our study showed no statistically significant difference in effectiveness and toxicity risk between the 12-h and 24-h regimens.Keywords
This publication has 23 references indexed in Scilit:
- Comparison of Zuspan regimen and its 12-hour modification in women with severe pre-eclampsia and eclampsia in two hospitals in AbeokutaPregnancy Hypertension, 2023
- A novel 12‐hour versus 24‐hour magnesium sulfate regimen in the management of eclampsia and preeclampsia in Ghana (MOPEP Study): A randomized controlled trialInternational Journal of Gynecology & Obstetrics, 2022
- Preeclampsia and eclampsia: the conceptual evolution of a syndromeAmerican Journal of Obstetrics and Gynecology, 2022
- Duration of postpartum magnesium sulfate for seizure prophylaxis in women with preeclampsia: a systematic review and meta-analysisThe Journal of Maternal-Fetal & Neonatal Medicine, 2021
- Shortened postpartum magnesium sulfate treatment vs traditional 24h for severe preeclampsia: a systematic review and meta-analysis of randomized trialsHypertension in Pregnancy, 2020
- Intravenous magnesium sulfate in the management of severe pre‐eclampsia: A randomized study of 12‐hour versus 24‐hour maintenance doseInternational Journal of Gynecology & Obstetrics, 2019
- Maternal outcomes after 12 hours and 24 hours of magnesium sulfate therapy for eclampsiaInternational Journal of Gynecology & Obstetrics, 2015
- Abbreviated (12‐hour) versus traditional (24‐hour) postpartum magnesium sulfate therapy in severe pre‐eclampsiaInternational Journal of Gynecology & Obstetrics, 2014
- Abbreviated Postpartum Magnesium Sulfate Therapy for Women With Mild PreeclampsiaObstetrics & Gynecology, 2006
- History and Epidemiology of Preeclampsia - EclampsiaClinical Obstetrics & Gynecology, 1984